The New Possibilities in Early Diagnosis of Preeclampsia by Soluble fms-Like Tyrosine Kinase-1 and Placental Growth Factor in 16-20 Weeks Gestation

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F65269705%3A_____%2F18%3A00069110" target="_blank" >RIV/65269705:_____/18:00069110 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216224:14110/18:00104136

Výsledek na webu

<a href="http://dx.doi.org/10.1093/labmed/lmx076" target="_blank" >http://dx.doi.org/10.1093/labmed/lmx076</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1093/labmed/lmx076" target="_blank" >10.1093/labmed/lmx076</a>

Jazyk výsledku

angličtina

Název v původním jazyce

The New Possibilities in Early Diagnosis of Preeclampsia by Soluble fms-Like Tyrosine Kinase-1 and Placental Growth Factor in 16-20 Weeks Gestation

Popis výsledku v původním jazyce

Background: Soluble fms-like tyrosine kinase-1 (sFlt-1) and placental growth factor (PIGF) ate used in diagnosing preeclampsia (PE), but their potential in early prediction in pregnant women at 16 to 20 weeks gestation (WG) has remained unexplored. Methods: We retrospectively measured serum levels of sFlt-1 and PIGF in 120 pregnant women at 16 to 20 WG. Among these women, 16 had early-onset PE and 23 had late-onset PE. Results: Compared with normal pregnancy values, in the serum of women in whom PE later developed, sFlt-1 values increased (P &lt;.001), values of PIGF decreased (P = .001), and the sFlt-1/PIGF ratio increased (P &lt;.001) as early as 16 to 20 WG. Receiver operating characteristic (ROC) curve analysis for the sFlt-1/PIGF ratio at 16 to 20 WG showed an area under the curve (AUC) value of 0.863 (95% confidence interval [CI], 0.788-0.918), P &lt;.001, sensitivity of 74.4%, and specificity of 86.6 degrees k for PE in general; and AUC of 0.970 (95% CI, 0.913-0.994), P &lt;.001, sensitivity of 100%, and specificity of 81.5% for early-onset PE only. Also, we determined the 5th and 95th percentiles for sFlt-1, PIGF, and sFlt-1/PIGF ratio values of healthy pregnant women. Conclusion: sFlt-1 and PIGF and, in particular, the sFlt-1/PIGF ratio can detect PE as early as 16 to 20 WG-as long as 10 to 15 weeks before PE onset.

Název v anglickém jazyce

The New Possibilities in Early Diagnosis of Preeclampsia by Soluble fms-Like Tyrosine Kinase-1 and Placental Growth Factor in 16-20 Weeks Gestation

Popis výsledku anglicky

Background: Soluble fms-like tyrosine kinase-1 (sFlt-1) and placental growth factor (PIGF) ate used in diagnosing preeclampsia (PE), but their potential in early prediction in pregnant women at 16 to 20 weeks gestation (WG) has remained unexplored. Methods: We retrospectively measured serum levels of sFlt-1 and PIGF in 120 pregnant women at 16 to 20 WG. Among these women, 16 had early-onset PE and 23 had late-onset PE. Results: Compared with normal pregnancy values, in the serum of women in whom PE later developed, sFlt-1 values increased (P &lt;.001), values of PIGF decreased (P = .001), and the sFlt-1/PIGF ratio increased (P &lt;.001) as early as 16 to 20 WG. Receiver operating characteristic (ROC) curve analysis for the sFlt-1/PIGF ratio at 16 to 20 WG showed an area under the curve (AUC) value of 0.863 (95% confidence interval [CI], 0.788-0.918), P &lt;.001, sensitivity of 74.4%, and specificity of 86.6 degrees k for PE in general; and AUC of 0.970 (95% CI, 0.913-0.994), P &lt;.001, sensitivity of 100%, and specificity of 81.5% for early-onset PE only. Also, we determined the 5th and 95th percentiles for sFlt-1, PIGF, and sFlt-1/PIGF ratio values of healthy pregnant women. Conclusion: sFlt-1 and PIGF and, in particular, the sFlt-1/PIGF ratio can detect PE as early as 16 to 20 WG-as long as 10 to 15 weeks before PE onset.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

20602 - Medical laboratory technology (including laboratory samples analysis; diagnostic technologies) (Biomaterials to be 2.9 [physical characteristics of living material as related to medical implants, devices, sensors])

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2018

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Laboratory medicine

ISSN

0007-5027

e-ISSN

—

Svazek periodika

49

Číslo periodika v rámci svazku

2

Stát vydavatele periodika

GB - Spojené království Velké Británie a Severního Irska

Počet stran výsledku

6

Strana od-do

112-117

Kód UT WoS článku

000435092600006

EID výsledku v databázi Scopus

2-s2.0-85044665182